N4 Pharma plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its current work streams. Collaborations As
SP Angel’s Vadim Alexandre discusses N4 Pharma plc in this exclusive interview with DirectorsTalk.
N4 Pharma plc (LON:N4P) is the topic of conversation when SP Angel Analyst Vadim Alexandre joins DirectorsTalk. Vadim talks us through the main points of their latest research note, explains
N4 Pharma’s Nigel Theobald discusses the Material Transfer Agreements, collaborating with more partners, the in vivo studies, how the work done under the MTA may negate the need for the Company to do its own proof of concept work and what investors can expect in the coming months in this exclusive interview with DirectorsTalk.
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its operations update. Nigel explains what is involved in the Material Transfer Agreements that have been announced, whether these
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on collaboration discussions and its ongoing in vivo work
N4 Pharma’s Nigel Theobald discusses final results, updates on the three work streams, the European patent for Nuvec & what this means for the company and what investors can expect in the near future in this exclusive interview with DirectorsTalk.
N4 Pharma Plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss results for the year ended 31 December 2020. Nigel talks us through the highlights of the year, updates us on
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
